Cutler Group’s Altamira Therapeutics Ltd CYTO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1
| Closed | – | – | 4586 |
|
|
2023
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 4489 |
|
|
2023
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 4377 |
|
|
2023
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 4988 |
|
|
2022
Q4 | $0 | Sell |
1
-7
| -88% | -$813 | ﹤0.01% | 5492 |
|
|
2022
Q3 | $0 | Hold |
8
| – | – | ﹤0.01% | 5725 |
|
|
2022
Q2 | $1K | Buy |
8
+3
| +60% | +$968 | ﹤0.01% | 4820 |
|
|
2022
Q1 | $2K | Buy |
5
+2
| +67% | +$966 | ﹤0.01% | 4830 |
|
|
2021
Q4 | $2K | Hold |
3
| – | – | ﹤0.01% | 4882 |
|
|
2021
Q3 | $2K | Buy |
3
+2
| +200% | +$2.25K | ﹤0.01% | 5158 |
|
|
2021
Q2 | $1K | Buy |
+1
| New | +$1.37K | ﹤0.01% | 5504 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 4939 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 4776 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 4873 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 5093 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 5441 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 4260 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 4907 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 5124 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 4084 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 3789 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 2870 |
|
Other funds holding CYTO
Cutler Group's CYTO Position: Q4 2023 in Review
Cutler Group sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2023, closing a stake of 1 share.
Cutler Group first reported a position in CYTO in Q2 2021 and held it in 10 quarters. The position peaked at $2K in Q1 2022. 4 funds tracked by Wall St. Rank hold CYTO as of Q4 2023.
- Cutler Group reported no remaining Altamira Therapeutics Ltd position as of Q4 2023 after selling out during the quarter.
- Cutler Group sold 1 Altamira Therapeutics Ltd share in Q4 2023.
- Cutler Group first reported a position in Altamira Therapeutics Ltd in Q2 2021 and held it in 10 quarters.
- Cutler Group's Altamira Therapeutics Ltd position peaked at $2K in Q1 2022.
- 4 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2023.
Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.